Zealand Pharma
Ascendis gets the nod in Europe and Camurus wins Canada as Nordic outperformance widens – the Nordic Pulse | 2026:42
Analytics
Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41
Upp till 9,2 procents viktnedgång för Zealands amylinkandidat
Zealand Pharma rapporterar positiva toplineresultat från fas II-studien...
Bioteknik
Obesitas
Egetis wins FDA approval, Indices retreat across the board – the Nordic Pulse | 2026:40
A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3
Analytics
Nanexa lands billion-euro Novo deal, Nordic index slides nearly three per cent – the Nordic Pulse | 2026:39
Oncopeptides rides the CHMP wave, AstraZeneca adds eight more years – the Nordic Pulse | 2026:38
Consensus Analysis | Zealand Pharma | 2026-08-25
De största affärerna inom nordisk life science 2026
Ett svenskt Alzheimerbolag dubblerade sin egen miljardaffär på...
Bioteknik
Demant raises the bar, XVIVO clears hearts and Zealand cashes in – the Nordic Pulse | 2026:33
Novo raises outlook, BioInvent breaks through, Nordics tread water – the Nordic Pulse | 2026:32
Zealand Pharmas faller på resultat
Zealand Pharma och Boehringer Ingelheim presenterade i helgen...
Bioteknik
